Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large …
TC Villines, A Ahmad, M Petrini, W Tang… - European Heart …, 2019 - academic.oup.com
… Among NVAF patients newly initiated on standard-dose DOAC therapy in this study,
dabigatran was associated with … rivaroxaban, and no significant difference in stroke risk. For …
dabigatran was associated with … rivaroxaban, and no significant difference in stroke risk. For …
Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention in incident, treatment-naive nonvalvular atrial fibrillation
… Cohort Selection and Data Source This observational cohort study used the Truven Health
Analytics MarketScan database. MarketScan data are administrative claims data that includes …
Analytics MarketScan database. MarketScan data are administrative claims data that includes …
Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: a population-based cohort study
… patient had a NOAC supply available. Because dosing guidelines for each NOAC are uniform
for all patients with atrial fibrillation… dosing for apixaban and dabigatran. When multiple …
for all patients with atrial fibrillation… dosing for apixaban and dabigatran. When multiple …
… Elderly (≥ 85 years) Patients With Newly Diagnosed Atrial Fibrillation: Changing Clinical Practice and Outcomes for Stroke Prevention in a Nationwide Cohort Study
WH Cheng, CE Chiang, YJ Lin, SL Chang, LW Lo… - Mayo Clinic …, 2021 - Elsevier
… were prescribed with OACs after AF was newly diagnosed (warfarin in 8.1%, dabigatran in
6.4%, rivaroxaban in 14.5%, and apixaban in 5.3%). NOACs consisted of approximately 76.4…
6.4%, rivaroxaban in 14.5%, and apixaban in 5.3%). NOACs consisted of approximately 76.4…
Should oral anticoagulants still be prescribed to patients with atrial fibrillation with a single stroke risk factor but at high bleeding risk? A nationwide cohort study
TF Chao, YH Chan, TC Tuan, JN Liao… - … Journal-Quality of …, 2022 - academic.oup.com
… There are several limitations of the present study, and some have been described
previously. First, this study is based on a nationwide cohort study based on the Taiwan National …
previously. First, this study is based on a nationwide cohort study based on the Taiwan National …
Three-year clinical outcomes associated with warfarin vs. direct oral anticoagulant use among Japanese patients with atrial fibrillation―findings from the SAKURA AF …
Y Okumura, K Yokoyama, N Matsumoto… - Circulation …, 2018 - jstage.jst.go.jp
… on the clinical use of DOACs nationwide. The aims of the registry-based … between warfarin
users and users of dabigatran, rivaroxaban, or apixaban. Third, equivalence in terms of stroke …
users and users of dabigatran, rivaroxaban, or apixaban. Third, equivalence in terms of stroke …
… stroke/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin …
… apixaban/dabigatran/rivaroxaban/warfarin) … nationwide cohort studies from the USA and
Europe have shown worse effectiveness outcomes with reduced NOAC doses than with warfarin …
Europe have shown worse effectiveness outcomes with reduced NOAC doses than with warfarin …
Ischemic stroke risk estimation in patients without oral anticoagulation: an observational cohort study based on secondary data from Germany
FS Wicke, MA Schaller, K Karymova, M Beyer… - BMC cardiovascular …, 2019 - Springer
… for ischemic stroke prevention in patients with atrial fibrillation (AF), stroke risk … study
design is a retrospective cohort study on patients with atrial fibrillation based on secondary …
design is a retrospective cohort study on patients with atrial fibrillation based on secondary …
Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of …
S Kohsaka, J Katada, K Saito, A Jenkins, B Li… - Open …, 2020 - openheart.bmj.com
… . Risk of stroke/systemic embolism, major bleeding and associated costs in non-… atrial
fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the …
fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the …
Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation
G Adeboyeje, G Sylwestrzak, JJ Barron, J White… - Journal of managed …, 2017 - jmcp.org
… of long-term anticoagulation with the newer agents in NVAF patients in routine … cohort
study, we compared major bleeding outcomes for NVAF patients treated with warfarin, dabigatran…
study, we compared major bleeding outcomes for NVAF patients treated with warfarin, dabigatran…